Analysts at StockNews.com started coverage on shares of Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) in a research report issued on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.
Adamis Pharmaceuticals Stock Performance
Shares of ADMP opened at $0.25 on Friday. The company’s fifty day moving average is $0.36 and its 200 day moving average is $0.44. Adamis Pharmaceuticals has a fifty-two week low of $0.18 and a fifty-two week high of $1.48.
Adamis Pharmaceuticals (NASDAQ:ADMP – Get Rating) last posted its quarterly earnings data on Wednesday, August 10th. The specialty pharmaceutical company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $1.02 million. As a group, sell-side analysts anticipate that Adamis Pharmaceuticals will post -0.18 earnings per share for the current year.
Institutional Inflows and Outflows
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States. The company's product candidates comprise SYMJEPI epinephrine pre-filled syringe injectable products for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products for the treatment of asthma; and naloxone injection for the treatment of opioid overdose.
- Get a free copy of the StockNews.com research report on Adamis Pharmaceuticals (ADMP)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.